IC31®, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice

Scandinavian Journal of Immunology

Volumn 69, Issue 3, 2009, Pages 194-202

  Olafsdottir, T A ^a,b   Lingnau, K ^c   Nagy, E ^c   Jonsdottir, I ^a,b,d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c INTERCELL AG   (Austria)

^d DECODE GENETICS   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL POLYSACCHARIDE TETANUS TOXOID CONJUGATE; CPG OLIGODEOXYNUCLEOTIDE; IC 31; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOLOGICAL ADJUVANT; TETANUS TOXOID; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; LYSYL LEUCYL LYSYL LEUCYL LEUCYL LEUCYL LEUCYL LEUCYL LYSYL LEUCYL LYSINE; LYSYL-LEUCYL-LYSYL-LEUCYL-LEUCYL-LEUCYL-LEUCYL-LEUCYL-LYSYL-LEUCYL-LYSINE; OLIGODEOXYRIBONUCLEOTIDE; OLIGOPEPTIDE; PNEUMOCOCCUS VACCINE; VACCINE;

ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTEREMIA; BACTERIAL IMMUNITY; BLOOD ANALYSIS; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HUMORAL IMMUNITY; IMMUNOGENICITY; LOW DRUG DOSE; LUNG HOMOGENATE; LUNG INFECTION; MONOTHERAPY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; WEIGHT GAIN; ANIMAL; BACTERIAL COUNT; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MICROBIOLOGY; NONPARAMETRIC TEST; PNEUMOCOCCAL INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; COLONY COUNT, MICROBIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; OLIGODEOXYRIBONUCLEOTIDES; OLIGOPEPTIDES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STATISTICS, NONPARAMETRIC; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 60349123505     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02225.x     Document Type: Article

References (37)

1. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992 165 (Suppl. 1 S49 52.
2. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000 19 : 187 95.
3. Cutts FT, Zaman SM, Enwere G et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005 365 : 1139 46.
4. Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002 21 : 810 5.
5. Black S, France EK, Isaacman D et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007 26 : 771 7.
6. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001 344 : 403 9.
7. O'Brien KL, David AB, Chandran A et al. Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr Infect Dis J 2008 27 : 71 3.
8. Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003 2 : 167 88.
9. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007 5 : 505 17.
10. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007 4 : 289 94.
11. Takeshita F, Leifer CA, Gursel I et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001 167 : 3555 8.
12. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000 408 : 740 5.
13. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000 192 : 595 600.
14. Vollmer J, Weeratna R, Payette P et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004 34 : 251 62.
15. Boman HG. Innate immunity and the normal microflora. Immunol Rev 2000 173 : 5 16.
16. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002 23 : 291 6.
17. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001 167 : 623 7.
18. Alvarez-Bravo J, Kurata S, Natori S. Novel synthetic antimicrobial peptides effective against methicillin-resistant Staphylococcus aureus. Biochem J 1994 302 (Pt 2 535 8.
19. Fritz JH, Brunner S, Birnstiel ML et al. The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 2004 22 : 3274 84.
20. Schellack C, Prinz K, Egyed A et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006 24 : 5461 72.
21. Agger EM, Rosenkrands I, Olsen AW et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 2006 24 : 5452 60.
22. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. The novel adjuvant IC31(R) strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 2008 26 : 3461 8.
23. Kamath AT, Valenti MP, Rochat AF et al. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol 2008 38 : 1247 56.
24. Saeland E, Vidarsson G, Jonsdottir I. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb Pathog 2000 29 : 81 91.
25. Jakobsen H, Bjarnarson SP, Del Giudice G, Moreau M, Siegrist CA, Jonsdottir I. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 2002 70 : 1443 52.
26. Jakobsen H, Saeland E, Gizurarson S, Schulz D, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun 1999 67 : 4128 33.
27. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001 19 : 3331 46.
28. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005 11 : S54 62.
29. Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 1999 67 : 5892 7.
30. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004 22 : 2209 20.
31. Saeland E, Jakobsen H, Ingolfsdottir G, Sigurdardottir ST, Jonsdottir I. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J Infect Dis 2001 183 : 253 60.
32. Olafsdottir TA, Hannesdottir SG, Giudice GD, Trannoy E, Jonsdottir I. Effects of LT-K63 and CpG2006 on phenotype and function of murine neonatal lymphoid cells. Scand J Immunol 2007 66 : 426 34.
33. Hannesdottir SG, Olafsdottir TA, Giudice GD, Jonsdottir I. Adjuvants LT-K63 and CpG enhance the activation of dendritic cells in neonatal mice. Scand J Immunol 2008 68 : 469 75.
34. Lipford GB, Sparwasser T, Bauer M et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol 1997 27 : 3420 6.
35. Sparwasser T, Miethke T, Lipford G et al. Bacterial DNA causes septic shock. Nature 1997 386 : 336 7.
36. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 1969 129 : 1385 95.
37. Eiosson SF, Giuliani M, Ólafsdóttir TA, Pizza M, Rappuoli R, Jónsdóttir I. Formulations of five conserved meningococcal B virulence proteins, 5CVMB, with safe adjuvants elicit broadly protective antibody responses in neonatal mice. Abstract P103. In : ed. Proceedings of the 16th International Pathogenic Neisseria Conference, Rotterdam, The Netherlands, 7-12 September, 2008. Beurs World Trade Center, pp. 173 4.